ALIGN TECHNOLOGY INC 10-Q

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. Forward-Looking Statements In addition to historical information, this quarterly report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements include, among other things, our expectations and intentions regarding our strategic objectives and the means to achieve them, our beliefs regarding digital dentistry and its potential to impact our business, our intentions regarding expanding our business, our expectations regarding the utilization rates for our products, including the impact of marketing on those rates and causes for periodic fluctuations of the rates, our expectation regarding customer and consumer purchasing behavior, including expectations related to consumer demand for digital solutions, our expectations for future investments in and benefits from consumer demand sales and marketing activities, our expectations regarding the near and long-term implications of the COVID-19 pandemic on the global economy, the businesses of our customers, and us, including our preparedness to react to changing circumstances and demand, results of operations and financial condition, our expectations for our expenses and capital obligations and expenditures in particular, the actions we will take to control spending and for investments, our intentions regarding the investment of our international earnings from operations, our belief regarding the sufficiency of our cash balances and borrowing capacity, our judgments regarding the estimates used in our revenue recognition, and assessment of goodwill and intangible assets, our expectations regarding our tax positions and the judgments we make related to our tax obligations, our expectations regarding potential litigation with SDC Financial LLC, the level of our operating expenses and gross margins and other factors beyond our control, as well as other statements regarding our future operations, financial condition and prospects and business strategies. These statements may contain words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” or other words indicating future results. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in Item 2 “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and in particular, the risks discussed below in Part 2, Item 1A “Risk Factors.” We undertake no obligation to revise or update these forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The following discussion and analysis of our financial condition and results of operations should be read together with our condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q and with our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission. Executive Overview of Results COVID-19 Update Since the first quarter of fiscal year 2020, our sales and results of operations have been impacted first by the preventative measures implemented to slow the spread of COVID-19, including the complete closure or significantly reduced operations of dental practices and, more recently, the inconsistent pace and scale of recovery in various markets. In 2021, the pandemic continues to cause general business and societal disruptions and uncertainties worldwide, although many of the most drastic measures imposed to prevent or limit the spread of the virus have been moderated. For instance, globally dental practices both public and private, have largely reopened, although many continue to operate at less than pre-pandemic capacities. Conversely, as a result of the restrictive measures imposed to contain the spread of the virus, the demand for digital solutions has increased as society and businesses have adapted to such practices as social distancing and remote working. Our efforts to promote the digital transformation of dental practices with our clear aligners, intraoral scanners, clinical treatment planning and other offerings has allowed us to quickly respond to increased demand in the dental field. We expect a growing number of customers to realize the efficiencies and benefits of our digital solutions for their practices and patients even as the pandemic-related restrictions continue to ease. To address the increasing demand for digital solutions, we intend to continue targeting our investment plans, including, in the areas of sales, marketing, innovation and capital expenditures. As we expand our manufacturing operations in locations such as Europe, prepare for the safe return of employees to our offices and experiment with hybrid work models in 2021, we expect our sales and marketing as well as capital expenditures to increase as we focus our efforts to meet the growing demand we anticipate for our solutions. Nevertheless, the continuing evolution of the pandemic, including any setbacks as a result of any new virus strains or business restrictions or lockdowns, the positive impacts of vaccinations, the uncertainties regarding consumer spending as 22 Table of Contents demand for entertainment, dining, travel returns and remote working diminishes, remains highly fluid and unpredictable. As such, our recent operating results and levels of growth may not be indicative of our future performance and comparisons to prior quarters and periods in 2020. Ultimately, however, we believe the digital transition to dentistry that began before the pandemic will continue to be positive for our business, results of operations, cash flows, and financial condition and we intend to adjust spending to coincide with the pace of recovery and changes in demand. Further discussion of the impact of the COVID-19 pandemic on our business may be found in Item 1A of this Quarterly Report on Form 10-Q under the heading “Risk Factors.” Key financial and operating metrics Our business strategic priorities remain focused on four principal pillars of growth: (i) International expansion; (ii) GP adoption; (iii) Patient demand & conversion; and (iv) Orthodontic utilization. We measure our performance against these strategic priorities by the achievement of key financial and operating metrics. For the three months ended March 31, 2021, we achieved: • Revenues of $894.8 million and revenue growth of 62.4% year-over-year; • Clear Aligner revenues of $753.3 million with revenue growth of 56.4% year-over-year; • Imaging Systems and CAD/CAM Services revenues of $141.5 million or 104.0% year-over-year growth including exocad’s revenues; • Clear Aligner volume increased by 65.8% year-over-year and Clear Aligner volume for teenage patients increased by 58.9% year-over-year; • Income from operations $225.4 million and operating margin 25.2%; • Effective tax rate was 23.4%; • Net income of $200.4 million with diluted net income per share of $2.51; • Cash and cash equivalents were $1.1 billion as of March 31, 2021; • Operating cash flow was $227.2 million; • Capital expenditures were $43.4 million and predominantly relates to increasing our manufacturing capacity and facilities; and • Number of employees was 18,975 as of March 31, 2021 and increased 25.8% year-over-year Other Statistical Data and Trends • Digital Scanner Case Submissions. For the first quarter of 2021, total Invisalign cases submitted with a digital scanner in the Americas increased to 85.5%, up from 80.5% in the first quarter of 2020 and international scans increased to 75.1%, up from 68.7% in the first quarter of 2020. For the first quarter of 2021, 92.9% of Invisalign cases submitted by North American orthodontists were submitted digitally. Our quarterly utilization rates for the last five quarters are as follows: 23 Table of Contents * Invisalign utilization rates are calculated by the number of cases shipped divided by the number of doctors to whom cases were shipped. Our International region includes Europe, Middle East and Africa ( “ EMEA ” ) and Asia Pacific ( “ APAC ” ). Latin America ( “ LATAM ” ) is excluded from the International region based on its immateriality to the quarter, however is included in the Total utilization. • Total utilization rate in the first quarter of 2021 increased to 7.6 cases per doctor compared to 5.9 cases per doctor in the first quarter of 2020. ▪ North America: Utilization rate among our North American orthodontist customers increased to 26.8 cases per doctor in the first quarter of 2021 compared to 18.9 cases per doctor in the first quarter of 2020 and the utilization rate among our North American GP customers increased to 4.8 cases per doctor in the first quarter of 2021 compared to 3.6 cases per doctor in the first quarter of 2020. ▪ International: International doctor utilizat ion rate was 6.8 cases per doctor in the first quarter of 2021 compared to 5. 1 cas es in the first quarter of 2020. • International Invisalign Growth. For the three months ended March 31, 2021, International net revenues from Clear Aligners increased to $353.3 million compared to $195.8 million during the same period in 2020. Results of Operations Net Revenues by Reportable Segment We group our operations into two reportable segments: Clear Aligner segment and Systems and Services segment. • Our Clear Aligner segment consists of Comprehensive Products, Non-Comprehensive Products and Non-Case revenues as defined below: ▪ Comprehensive Products include, but are not limited to, Invisalign Comprehensive and Invisalign First. ▪ Non-Comprehensive Products include, but are not limited to, Invisalign Moderate, Lite and Express packages and Invisalign Go. ▪ Non-Case includes, but is not limited to, Vivera retainers along with our training and ancillary products for treating malocclusion. 24 Table of Contents • Our Systems and Services segment consists of our iTero intraoral scanning systems, which includes a single hardware platform and restorative or orthodontic software options, OrthoCAD services and ancillary products, as well as exocad ’ s CAD/CAM software solution that integrates workflows to dental labs and dental practices. Net revenues for our Clear Aligner and Systems and Services segments by region for the three months ended March 31, 2021 and 2020 are as follows (in millions): Three Months Ended March 31, Net Revenues 2021 2020 Change Clear Aligner net revenues: Americas $ 357.5 $ 255.6 $ 101.9 39.9 % International 353.3 195.8 157.5 80.4 % Non-case 42.5 30.2 12.3 40.8 % Total Clear Aligner net revenues $ 753.3 $ 481.6 $ 271.7 56.4 % Systems and Services net revenues 141.5 69.4 72.2 104.0 % Total net revenues $ 894.8 $ 551.0 $ 343.8 62.4 % Changes and percentages are based on actual values. Certain tables may not sum or recalculate due to rounding. Clear Aligner Case Volume Case volume data which represents Clear Aligner case shipments for the three months ended March 31, 2021 and 2020 is as follows (in thousands): Three Months Ended March 31, 2021 2020 Change Total case volume 595.8 359.4 236.4 65.8 % Changes and percentages are based on actual values. Certain tables may not sum or recalculate due to rounding. For the three months ended March 31, 2021, total net revenues increased by $343.8 million as compared to the same period in 2020 primarily as a result of Clear Aligner volume growth of 65.8% and an increase in the number of scanners recognized across all regions. Clear Aligner - Americas For the three months ended March 31, 2021, Americas net revenues increased by $101.9 million as compared to the same period in 2020 primarily due to Clear Aligner volume growth of 53.8% which increased net revenues by $137.6 million partially offset by lower Clear Aligner ASP that decreased net revenues by $35.7 million. Lower ASP was mostly due to higher promotional discounts which decreased net revenues by $19.1 million and higher net deferrals which decreased net revenues by $12.5 million. Clear Aligner - International For the three months ended March 31, 2021, International net revenues increased by $157.5 million as compared to the same period in 2020 primarily due to Clear Aligner volume growth of 83.2% which increased net revenues by $162.9 million partially offset by lower Clear Aligner ASP. Lower ASP was the result of higher net revenue deferrals partially offset by favorable foreign exchange rates. Clear Aligner - Non-Case For the three months ended March 31, 2021, non-case net revenues increased by $12.3 million as compared to the same period in 2020 due to increased Vivera volume across all regions. Systems and Services For the three months ended March 31, 2021, Systems and Services net revenues increased by $72.2 million as compared to the same period in 2020 due to a higher number of scanners recognized which increased net revenues by $47.2 million. 25 Table of Contents Additionally, net revenues increased by $23.6 million as a result of higher iTero service revenues mostly due to a larger scanner install base and the addition of exocad’s CAD/CAM revenues. Cost of net revenues and gross profit (in millions): Three Months Ended March 31, 2021 2020 Change Clear Aligner Cost of net revenues $ 168.7 $ 130.1 $ 38.6 % of net segment revenues 22.4 % 27.0 % Gross profit $ 584.5 $ 351.5 $ 233.0 Gross margin % 77.6 % 73.0 % Systems and Services Cost of net revenues $ 48.9 $ 26.5 $ 22.5 % of net segment revenues 34.6 % 38.2 % Gross profit $ 92.6 $ 42.9 $ 49.7 Gross margin % 65.4 % 61.8 % Total cost of net revenues $ 217.7 $ 156.6 $ 61.1 % of net revenues 24.3 % 28.4 % Gross profit $ 677.1 $ 394.4 $ 282.7 Gross margin % 75.7 % 71.6 % Changes and percentages are based on actual values. Certain tables may not sum or recalculate due to rounding. Cost of net revenues includes personnel-related costs including payroll and stock-based compensation for staff involved in the production process, the cost of materials, packaging, shipping costs, depreciation on capital equipment and facilities used in the production process, amortization of acquired intangible assets and training costs. Clear Aligner For the three months ended March 31, 2021, our gross margin percentage increased as compared to the same period in 2020 primarily due to manufacturing efficiencies driven by higher production volumes which was partially offset by lower ASP. Systems and Services For the three months ended March 31, 2021, our gross margin percentage increased as compared to the same period in 2020 primarily driven by manufacturing efficiencies driven by higher production volumes and higher ASP from a product mix shift. Selling, general and administrative (in millions): Three Months Ended March 31, 2021 2020 Change Selling, general and administrative $ 397.1 $ 282.9 $ 114.2 % of net revenues 44.4 % 51.3 % Changes and percentages are based on actual values. Certain tables may not sum or recalculate due to rounding. Selling, general and administrative expense generally includes personnel-related costs including payroll, stock-based compensation and commissions for our sales force, marketing and advertising expenses inc luding media, public relations, marketing materials, clinical education, trade shows and industry events, legal and outside service cos ts, equipment, software and maintenance costs, depreciation and amortization expense and allocations of corporate overhead expenses including facilities and Information Technology (“IT”). 26 Table of Contents For the three months ended March 31, 2021, selling, general and administrative expense increased compared to the same period in 2020 primarily due to higher compensation related costs of $63.3 million mainly from higher salaries, fringe benefits, incentive bonuses, commissions and stock-based compensation. Higher salaries were driven by an increase in headcount of approximately 23% as we continue to invest in sales and marketing to penetrate into new markets. Additionally, we also incurred higher advertising and marketing costs of $29.6 million during the three months ended March 31, 2021. Research and development (in millions): Three Months Ended March 31, 2021 2020 Change Research and development $ 54.5 $ 41.5 $ 13.0 % of net revenues 6.1 % 7.5 % Changes and percentages are based on actual values. Certain tables may not sum or recalculate due to rounding. Research and development expense generally includes personnel-related costs including payroll and stock-based compensation, software, equipment, material and maintenance costs, outside service costs associated with the research and development of new products and enhancements to existing products, depreciation and amortization expense and allocations of corporate overhead expenses including facilities and IT. For the three months ended March 31, 2021, research and development expense increased compared to the same period in 2020 primarily due to higher compensation costs including higher salaries, fringe benefits, and incentive bonuses which was driven by an approximate 29% increase in headcount. Income from operations (in millions): Three Months Ended March 31, 2021 2020 Change Clear Aligner Income from operations $ 327.5 $ 166.4 $ 161.1 Operating margin % 43.5 % 34.5 % Systems and Services Income from operations $ 47.2 $ 14.4 $ 32.8 Operating margin % 33.4 % 20.7 % Total income from operations 1 $ 225.4 $ 69.9 $ 155.5 Operating margin % 25.2 % 12.7 % Changes and percentages are based on actual values. Certain tables may not sum or recalculate due to rounding. 1 Refer to Note 12 “Segments and Geographical Information” of the Notes to Condensed Consolidated Financial Statements for details on unallocated corporate expenses and the reconciliation to Condensed Consolidated Income from Operations. Clear Aligner For the three months ended March 31, 2021, our operating margin percentage increased compared to the same period in 2020 due to a higher gross margin and operating leverage on higher net revenues. Systems and Services For the three months ended March 31, 2021, our operating margin percentage increased compared to the same period in 2020 due to operating leverage on higher net revenues in addition to a higher gross margin. 27 Table of Contents Interest income (in millions): Three Months Ended March 31, 2021 2020 Change Interest income $ 1.6 $ 2.0 $ (0.3) % of net revenues 0.2 % 0.4 % Changes and percentages are based on actual values. Certain tables may not sum or recalculate due to rounding. Interest income generally includes interest earned on cash, cash equivalents and investment balances. For the three months ended March 31, 2021, interest income decreased compared to the same period in 2020 mainly due to the divestiture of our marketable securities portfolio during the first quarter of 2020 mostly offset by interest income recognized during the three months ended March 31, 2021 from the SDC arbitration award regarding the value of Align’s capital account balance. Other income (expense), net (in millions): Three Months Ended March 31, 2021 2020 Change Other income (expense), net $ 34.5 $ (18.5) $ 53.1 % of net revenues 3.9 % (3.4) % Changes and percentages are based on actual values. Certain tables may not sum or recalculate due to rounding. Other income (expense), net, generally includes foreign exchange gains and losses, gains and losses on foreign currency forward contracts, interest expense, gains and losses on equity investments and other miscellaneous charges. For the three months ended March 31, 2021, other income (expense), net increased compared to the same period in 2020 primarily due to a $43.4 million gain related to the SDC arbitration award in the current period in addition to a $9.2 million unrealized loss on a foreign currency forward contract related to the exocad acquisition recognized during the same period in 2020. Provision for (benefit from) income taxes (in millions): Three Months Ended March 31, 2021 2020 Change Provision for (benefit from) income taxes $ 61.2 $ (1,464.8) $ 1,526.0 Effective tax rates 23.4 % (2,745.3) % Changes and percentages are based on actual values. Certain tables may not sum or recalculate due to rounding. Our provision for income taxes was $61.2 million for the three months ended March 31, 2021 and our benefit from income taxes was $1,464.8 million for the three months ended March 31, 2020 representing effective tax rates of 23.4% and (2,745.3)%, respectively. Our effective tax rate differs from the statutory federal income tax rate of 21% for the three months ended March 31, 2021 primarily due to the recognition of additional tax expense resulting from state income taxes, non-deductible expenses in the U.S. and foreign income taxed at different rates, partially offset by the recognition of excess tax benefits related to stock-based compensation. Our effective tax rate differs from the statutory federal income tax rate of 21% for the three months ended March 31, 2020 mainly as a result of the recognition of a deferred tax asset and related one-time tax benefit in accordance with the completion of the intra-entity transfer of certain intellectual property rights and fixed assets to our Swiss entity and excess tax benefits related to stock-based compensation, partially offset by state income taxes and foreign income taxed at different rates. The increase in our effective tax rate for the three months ended March 31, 2021 compared to the same period in 2020 is primarily attributable to the recognition of a deferred tax asset and related one-time tax benefit associated with the intra-entity transfer of certain intellectual property rights during the three months ended March 31, 2020, partially offset by increased tax benefits from certain foreign earnings being taxed at lower tax rates, reduced state income taxes, and non-deductible expenses in the U.S. 28 Table of Contents During the three months ended March 31, 2020, we completed an intra-entity transfer of certain intellectual property rights and fixed assets to our Swiss entity. The transfer of intellectual property rights did not result in a taxable gain; however, it did result in a step-up of the Swiss tax deductible basis in the transferred assets, and accordingly, created a temporary difference between the book basis and the tax basis of such intellectual property rights. Consequently, this transaction resulted in the recognition of a deferred tax asset and related one-time tax benefit of approximately $1,493.5 million during the three months ended March 31, 2020, which is the net impact of the deferred tax asset recognized as a result of the additional Swiss tax deductible basis in the transferred assets and certain costs related to the transfer of fixed assets and inventory. The amortization of this deferred tax asset depends on the profitability of our Swiss headquarters and the recognition of this tax benefit is allowed for a maximum recovery period of 15 years. Liquidity and Capital Resources Liquidity and Trends We fund our operations from product sales. As of March 31, 2021 and December 31, 2020, we had cash and cash equivalents, which are comprised of money market funds, of $1.1 billion and $960.8 million, respectively. As of March 31, 2021 and December 31, 2020, approximately $447.3 million and $412.5 million of cash and cash equivalents was held by our foreign subsidiaries, respectively. Our intent is to permanently reinvest our earnings from our international operations going forward, and our current plans do not require us to repatriate them to fund our U.S. operations as we generate sufficient domestic operating cash flow and have access to external funding under our $300.0 million revolving line of credit . We believe that our current cash balances and the borrowing capacity under our credit facility, if necessary, will be sufficient to fund our business for at least the next 12 months. For 2021, we expect our investments in capital expenditures to exceed $300.0 million. Capital expenditures primarily relate to building construction and improvements as well as additional manufacturing capacity to support our international expansion. This includes our planned investment in a new manufacturing facility in Wroclaw, Poland, our first one in the EMEA region. As we expand our manufacturing operations and penetrate into newer markets, prepare for the safe return of employees to our offices and experiment with hybrid work models in 2021, we also expect to invest significantly in sales, marketing and innovation to meet the growing demand for our solutions. As of March 31, 2021, we have $100.0 million available for repurchase under the share repurchase program authorized by our Board of Directors in May 2018. We entered into the 2021 ASR on April 30, 2021, to repurchase the remaining $100.0 million under the program. Additional information regarding the impact of COVID-19 on our liquidity and capital resources may be found in Item 1A of this Quarterly Report on Form 10-Q under the heading “ Risk Factors ” . Sources and Uses of Cash The following table summarizes our condensed consolidated cash flows for the three months ended March 31, 2021 and 2020 (in thousands): Three Months Ended March 31, 2021 2020 Net cash flow provided by (used in): Operating activities $ 227,187 $ 9,784 Investing activities 4,566 276,211 Financing activities (53,435) (34,733) Effect of exchange rate changes on cash, cash equivalents, and restricted cash (7,487) (11,007) Net increase in cash, cash equivalents, and restricted cash $ 170,831 $ 240,255 29 Table of Contents Operating Activities For the three months ended March 31, 2021, cash flows from operations of $227.2 million resulted primarily from our net income of approximately $200.4 million as well as the following: Significant non-cash activities • Gain related to our SDC arbitration award of $43.4 million; • Changes in deferred taxes of $29.0 million primarily related to current year amortization and adjustments to our deferred tax assets of our Swiss entity; • Stock-based compensation of $27.2 million related to equity awards granted to employees and directors; and • Depreciation and amortization of $25.6 million related to our investments in property, plant and equipment and intangible assets. Significant changes in working capital • Increase of $106.0 million in deferred revenues primarily related to increased cases volumes and timing of revenue recognition; • Increase of $67.4 million in accounts receivable which is primarily a result of the increase in sales and timing of our collections; and • Increase of $34.9 million in prepaid expenses and other assets due to the timing of payments and activities. Investing Activities Net cash provided by investing activities was $4.6 million for the three months ended March 31, 2021, which consisted of $43.4 million of proceeds from our SDC arbitration award in addition to $4.6 million received on an unsecured promissory note. These inflows were mostly offset by purchases of property and plant and equipment of $43.4 million. Financing Activities Net cash used in financing activities was $53.4 million for the three months ended March 31, 2021 which consisted of payroll taxes paid for equity awards through share withholdings of $66.6 million which was partially offset by $13.1 million of proceeds from the issuance of common stock. Contractual Obligations Our contractual obligations have not significantly changed since December 31, 2020 as disclosed in our Annual Report on Form 10-K, other than obligations described in the Form 10-Q herein, including items disclosed in Note 7 “ Commitments and Contingencies ” of the Notes to Condensed Consolidated Financial Statements . We believe that our current cash balances and the borrowing capacity under our credit facility, if necessary, will be sufficient to fund our business for at least the next 12 months. If we are unable to generate adequate operating cash flows and need more funds beyond our available liquid investments and those available under our credit facility, we may need to suspend our stock repurchase programs or seek additional sources of capital through equity or debt financing, collaborative or other arrangements with other companies, bank financing and other sources in order to realize our objectives and to continue our operations. There can be no assurance that we will be able to obtain additional debt or equity financing on terms acceptable to us, or at all. If adequate funds are not available, we may need to make business decisions that could adversely affect our operating results such as modifications to our pricing policy, business structure or operations. Accordingly, the failure to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on our business, results of operations and financial condition. Off-Balance Sheet Arrangements As of March 31, 2021, we had no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our consolidated financial condition, results of operations, liquidity, capital expenditures or capital resources other than certain items disclosed in Note 11 “ Commitments and Contingencies ” of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K. Critical Accounting Policies and Estimates Management’s discussion and analysis of our financial condition and results of operations is based upon our Condensed Consolidated Financial Statements, which have been prepared in accordance with accounting principles generally accepted in 30 Table of Contents the United States of America. The preparation of financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses and disclosures at the date of the financial statements. We evaluate our estimates on an on-going basis, including those related to revenue recognition, goodwill and finite-lived assets, business combination, income taxes and legal proceedings and litigations. We use authoritative pronouncements, historical experience and other assumptions as the basis for making estimates. Actual results could differ from those estimates. There have been no material changes to our critical accounting policies and estimates from the information provided in the “Critical Accounting Policies and Estimates” section of our Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2020. Recent Accounting Pronouncements See Note 1 “ Summary of Significant Accounting Policies ” of the Notes to Condensed Consolidated Financial Statements for a discussion of recent accounting pronouncements. ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK There have been no material changes in our market risk during the three months ended March 31, 2021, compared to the disclosure s in Part II, Item 7A of our Annual Report on Form 10-K for th e year ended December 31, 2020.